id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
11961411_3 | To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[105]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"histological abnormalities of the glomerulus\"]], \"start\": [[60]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"postoperative IFN-beta therapy\"]], \"start\": [[121]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"IFN-beta\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"malignant melanoma\"]], \"start\": [[160]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11020127_1 | Protease inhibitor-induced carbamazepine toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Protease inhibitor\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Protease inhibitor\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"carbamazepine toxicity\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11452688_1 | This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving 'standard' doses of dexamethasone as part of the antiemetic regimen used in cisplatin-based combination chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"bilateral avascular necrosis of the femoral heads\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[83]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"'standard' doses of dexamethasone\"]], \"start\": [[103]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"'standard' doses\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"dexamethasone\"]], \"start\": [[123]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7679525_3 | He recovered successfully after treatment with very high doses of corticosteroids and azathioprine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recovered\"]], \"start\": [[3]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"very high doses of corticosteroids and azathioprine\"]], \"start\": [[47]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"very high doses\"]], \"start\": [[47]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"azathioprine\"]], \"start\": [[66], [86]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[82]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"azathioprine\"]], \"start\": [[66], [86]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
717931_2 | Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Marked hyperkalemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"during and immediately after an infusion of arginine monohydrochloride\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"arginine monohydrochloride\"]], \"start\": [[77]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[65]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"immediately\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"hepatic disease\"]], \"start\": [[132]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"two patients with severe hepatic disease and moderate renal insufficiency\"]], \"start\": [[107]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[107]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"moderate renal insufficiency\"]], \"start\": [[152]], \"entity_id\": [\"T14\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[125]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
937377_1 | Finally, reserpine toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[90]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"reserpine toxicity, in particular central nervous system (CNS) disturbances\", \"additive CNS effects\"]], \"start\": [[9, 167]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"reserpine\", \"also receiving barbiturates,\"]], \"start\": [[9, 127]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"barbiturates\"], [\"reserpine\"]], \"start\": [[142], [9]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"also\"]], \"start\": [[127]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"barbiturates\"], [\"reserpine\"]], \"start\": [[142], [9]], \"entity_id\": [\"T6\", \"T7\"]}}]}}"
}
]
}
] |
14740795_3 | Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"amifostine\"]], \"start\": [[19]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amifostine\"]], \"start\": [[19]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"fever\"], [\"sepsis and fevers of neutropenia\"]], \"start\": [[47], [118]], \"entity_id\": [\"T8\", \"T11\"]}}"
}
]
}
] |
9215418_1 | Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hypermagnesemia\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"oral administration of magnesium sulfate\"]], \"start\": [[73]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"magnesium sulfate\"]], \"start\": [[96]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7408538_1 | Markedly increased pigmementation of skin immediately overlying veins used for multiple 5-fluorouracil infusions was noted. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"noted\"]], \"start\": [[117]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Markedly increased pigmementation of skin immediately overlying veins\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"multiple 5-fluorouracil infusions\"]], \"start\": [[79]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"infusions\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2140997_3 | Severe hepatitis caused by cyproterone acetate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Severe hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[27]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[27]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
14693027_2 | Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Erythema multiforme\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phenytoin and cranial radiation therapy\"]], \"start\": [[36]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[89]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[89]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
12967198_2 | Chloroquine has been used for many decades in the prophylaxis and treatment of malaria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Chloroquine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Chloroquine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"malaria\"]], \"start\": [[79]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"prophylaxis and treatment\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11414270_7 | Before ICU admission, the patient had suffered from painful mucositis causing severe dysphagia and bleeding, which was thought to be the result of chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[137]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"chemotherapy\"]], \"start\": [[147]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[147]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"severe dysphagia and bleeding\"]], \"start\": [[78]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"the patient had suffered from painful mucositis\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"mucositis\"]], \"start\": [[60]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3200786_3 | We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[165]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a patient with the acquired immunodeficiency syndrome\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[89]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[89]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"acquired immunodeficiency syndrome\"]], \"start\": [[41]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"adrenal failure\"]], \"start\": [[190]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9052919_3 | We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produce\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cyclosporin\", \"together with ganciclovir\"]], \"start\": [[18, 40]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ganciclovir\"], [\"cyclosporin\"]], \"start\": [[54], [18]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"together\"]], \"start\": [[40]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"cyclosporin\"], [\"ganciclovir\"]], \"start\": [[18], [54]], \"entity_id\": [\"T14\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"occasional patients\"]], \"start\": [[162]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"transient brain stem or neuromuscular dysfunction with eye movement abnormality\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"postulate\"]], \"start\": [[3]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
313865_1 | Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[123]], \"entity_id\": [\"T28\"]}, \"Subject\": {\"text\": [[\"Three patients\"]], \"start\": [[0]], \"entity_id\": [\"T25\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[0]], \"entity_id\": [\"T29\"]}}, \"Effect\": {\"text\": [[\"'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment)\"]], \"start\": [[139]], \"entity_id\": [\"T26\"]}, \"Treatment\": {\"text\": [[\"cytotoxic treatment, including high dose methotrexate with folinic acid rescue\"]], \"start\": [[43]], \"entity_id\": [\"T27\"], \"Disorder\": {\"text\": [[\"tumour\"]], \"start\": [[24]], \"entity_id\": [\"T30\"]}, \"Drug\": {\"text\": [[\"cytotoxic\"], [\"methotrexate\"], [\"folinic acid rescue\"]], \"start\": [[43], [84], [102]], \"entity_id\": [\"T31\", \"T32\", \"T33\"]}, \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[74]], \"entity_id\": [\"T35\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[97]], \"entity_id\": [\"T34\"]}, \"Drug\": {\"text\": [[\"folinic acid rescue\"], [\"methotrexate\"], [\"cytotoxic\"]], \"start\": [[102], [84], [43]], \"entity_id\": [\"T33\", \"T32\", \"T31\"]}}]}}"
}
]
}
] |
24846936_3 | Methylene blue-associated serotonin toxicity has been described before but usually as mild toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Methylene blue\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Methylene blue\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[86]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
12221670_2 | The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"found\"]], \"start\": [[107]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"neutropenic with marrow aplasia.\"]], \"start\": [[113]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"receiving ticlopidine for 2 years\"]], \"start\": [[34]], \"entity_id\": [\"T8\"], \"Duration\": {\"text\": [[\"2 years\"]], \"start\": [[60]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"82-year-old man\"]], \"start\": [[18]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"82-year-old\"]], \"start\": [[18]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19357764_3 | INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[102]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"stavudine\"]], \"start\": [[92]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"stavudine\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hyperlactatemia\"]], \"start\": [[110]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients on antiretroviral treatment\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"switched\"]], \"start\": [[136]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"patients on antiretroviral treatment\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"zidovudine\"]], \"start\": [[148]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"zidovudine\"]], \"start\": [[148]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"stavudine induced hyperlactatemia\"]], \"start\": [[92]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18633310_3 | We report a case of pediatric bupropion ingestion resulting in multiple seizures. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[50]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"pediatric\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"bupropion ingestion\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bupropion\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"multiple seizures\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18676387_8 | The co-administration of SSRIs and fentanyl may precipitate serotonin toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitate\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"co-administration of SSRIs and fentanyl\"]], \"start\": [[4]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"SSRIs\"], [\"fentanyl\"]], \"start\": [[25], [35]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"co-administration\"]], \"start\": [[4]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"SSRIs\"], [\"fentanyl\"]], \"start\": [[25], [35]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[44]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
19707032_5 | Three days after intravitreal injection of bevacizumab, acute ocular ischemic syndrome occurred. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[87]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Three days after intravitreal injection of bevacizumab\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"Three days\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"acute ocular ischemic syndrome\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
18453852_10 | After addition of lopinavir/ritonavir, eight volunteers suffered from both nausea and vomiting, one from nausea only, and one from vomiting only. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"lopinavir/ritonavir\"]], \"start\": [[18]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"lopinavir\"], [\"ritonavir\"]], \"start\": [[18], [28]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[27]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"lopinavir\"], [\"ritonavir\"]], \"start\": [[18], [28]], \"entity_id\": [\"T18\", \"T19\"]}}]}, \"Subject\": {\"text\": [[\"eight volunteers\"]], \"start\": [[39]], \"entity_id\": [\"T13\"], \"Population\": {\"text\": [[\"eight\"]], \"start\": [[39]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"nausea and vomiting\"]], \"start\": [[75]], \"entity_id\": [\"T15\"]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"lopinavir/ritonavir\"]], \"start\": [[18]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"lopinavir\"], [\"ritonavir\"]], \"start\": [[18], [28]], \"entity_id\": [\"T18\", \"T19\"]}}, \"Subject\": {\"text\": [[\"one\"]], \"start\": [[122]], \"entity_id\": [\"T23\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[122]], \"entity_id\": [\"T24\"]}}, \"Effect\": {\"text\": [[\"vomiting\"]], \"start\": [[131]], \"entity_id\": [\"T26\"]}}"
},
{
"event_id": "E4",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E4\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"lopinavir/ritonavir\"]], \"start\": [[18]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"lopinavir\"], [\"ritonavir\"]], \"start\": [[18], [28]], \"entity_id\": [\"T18\", \"T19\"]}}, \"Subject\": {\"text\": [[\"one\"]], \"start\": [[96]], \"entity_id\": [\"T21\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[96]], \"entity_id\": [\"T22\"]}}, \"Effect\": {\"text\": [[\"nausea\"]], \"start\": [[105]], \"entity_id\": [\"T25\"]}}"
}
]
}
] |
10357715_2 | Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"irritation of the skin\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Calcipotriol\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Calcipotriol\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[68]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
2309833_1 | After discontinuation of danazol the diabetes completely resolved. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"discontinuation of danazo\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"diabetes\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15977922_3 | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"woman\"]], \"start\": [[53]], \"entity_id\": [\"T9\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[53]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"ischemic colitis\"]], \"start\": [[31]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"tegaserod\"]], \"start\": [[80]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"tegaserod\"]], \"start\": [[80]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
11834188_4 | We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"cutaneous reaction\"]], \"start\": [[51]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[81]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[81]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11033734_4 | Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[40]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"Three of these patients\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"imipenem/cilastatin\"]], \"start\": [[54]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[54], [63]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[62]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[54], [63]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"convulsions\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E4",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E4\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[158]], \"entity_id\": [\"T24\"]}, \"Subject\": {\"text\": [[\"2%\"]], \"start\": [[112]], \"entity_id\": [\"T18\"], \"Population\": {\"text\": [[\"2%\"]], \"start\": [[112]], \"entity_id\": [\"T19\"]}}, \"Treatment\": {\"text\": [[\"imipenem/cilastatin\"]], \"start\": [[118]], \"entity_id\": [\"T20\"], \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[118], [127]], \"entity_id\": [\"T22\", \"T23\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[126]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"imipenem\"], [\"cilastatin\"]], \"start\": [[118], [127]], \"entity_id\": [\"T22\", \"T23\"]}}]}, \"Effect\": {\"text\": [[\"seizure\"]], \"start\": [[172]], \"entity_id\": [\"T25\"]}}"
}
]
}
] |
16225183_10 | This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"raises\"]], \"start\": [[94]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"potential renal toxicity\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"interferons\"]], \"start\": [[145]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"interferons\"]], \"start\": [[145]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"MS\"]], \"start\": [[160]], \"entity_id\": [\"T12\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[117]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
3101617_1 | Co-trimoxazole red cell aplasia in leukaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Co-trimoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"leukaemia\"]], \"start\": [[35]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"Co-trimoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"red cell aplasia\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12639299_1 | Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Interferon-alpha (IFN-alpha)\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Interferon-alpha (IFN-alpha)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"MPGN\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[29]], \"entity_id\": [\"T8\"], \"value\": true}, \"Severity\": {\"text\": [[\"precipitate or exacerbate\"]], \"start\": [[33]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
11207969_3 | Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"high-dose cytosine arabinoside\"]], \"start\": [[44]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Toxic epidermal necrolysis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
10981493_4 | We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"moderate to severe ataxia\"]], \"start\": [[36]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"taking propafenone\"]], \"start\": [[92]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[99]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"3 elderly patients\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
1445134_1 | Gestational diabetes was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with norethisterone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[98]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Gestational diabetes\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"norethisterone\"]], \"start\": [[114]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"norethisterone\"]], \"start\": [[114]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"no less severe\"]], \"start\": [[25]], \"entity_id\": [\"T7\"], \"value\": \"Medium\"}}"
}
]
}
] |
1445134_2 | However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"emerging\"]], \"start\": [[111]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"diabetes mellitus and impaired glucose tolerance\"]], \"start\": [[120]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"norethisterone\"]], \"start\": [[75]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"norethisterone\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"lesser risk\"]], \"start\": [[96]], \"entity_id\": [\"T11\"], \"value\": \"Low\"}}"
}
]
}
] |
3470173_1 | Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[127]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cerebellar toxicity\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"HDARAC\"]], \"start\": [[130]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"HDARAC\"]], \"start\": [[130]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2746565_3 | We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[43]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ibuprofen treatment\"]], \"start\": [[49]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"juvenile systemic lupus erythematosus\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"ulcerative proctitis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a girl with juvenile systemic lupus erythematosus\"]], \"start\": [[72]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[74]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9337441_18 | Clinicians should include phenolphthalein in their list of possible causes of drug-induced TEN. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenolphthalein\"]], \"start\": [[26]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"phenolphthalein\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
424824_4 | Methotrexate-induced diffuse interstitial pulmonary fibrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"diffuse interstitial pulmonary fibrosis\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16008658_2 | Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Abdominal wall ulceration and mucinosis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"recombinant human interferon-beta-1b\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"recombinant human interferon-beta-1b\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15661067_1 | Asthenozoospermia: possible association with long-term exposure to an anti-epileptic drug of carbamazepine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Asthenozoospermia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term exposure to an anti-epileptic drug of carbamazepine\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[19]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
15611427_2 | Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"triggered\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Psoriasis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"imiquimod\"]], \"start\": [[52]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"dermal plasmacytoid dendritic cell precursors\"]], \"start\": [[81]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6414095_3 | A 52-year-old Black woman on phenytoin therapy for post-traumatic epilepsy developed transient hemiparesis contralateral to the injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"transient hemiparesis contralateral to the injury\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[29]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"post-traumatic epilepsy\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[29]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"A 52-year-old Black woman\"]], \"start\": [[0]], \"entity_id\": [\"T11\"], \"Age\": {\"text\": [[\"52-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"Black\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[20]], \"entity_id\": [\"T14\"]}}, \"Severity\": {\"text\": [[\"transient\"]], \"start\": [[85]], \"entity_id\": [\"T15\"], \"value\": \"Low\"}}"
}
]
}
] |
18648015_4 | Use of the Naranjo probability scale determined the association between cephalosporin use and leukopenia to be probable. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[86]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cephalosporin\"]], \"start\": [[72]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cephalosporin\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[94]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[111]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
6142995_2 | Sister chromatid exchanges (SCEs), a sensitive measure of chromosome damage, were counted in peripheral-blood lymphocytes from 10 patients with Behcet's syndrome receiving chlorambucil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[162]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"10 patients with Behcet's syndrome\"]], \"start\": [[127]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"10\"]], \"start\": [[127]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"chlorambucil\"]], \"start\": [[172]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"Behcet's syndrome\"]], \"start\": [[144]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"chlorambucil\"]], \"start\": [[172]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"chromosome damage\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
876914_2 | Sarcoma complicating therapy with cyclophosphamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[8]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Sarcoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9260733_1 | Clozapine induced polyserositis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Clozapine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"polyserositis\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
20298401_1 | Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"interstitial lung disease\"]], \"start\": [[6]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[38]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[38]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with radiation fibrosis\"]], \"start\": [[66]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"radiation fibrosis\"]], \"start\": [[81]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"Medium\"}}"
}
]
}
] |
8586895_4 | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Halfan\", \"when a higher dose than recommended was used\"]], \"start\": [[37, 97]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Halfan\"], [\"mefloquine\"]], \"start\": [[37], [190]], \"entity_id\": [\"T10\", \"T12\"]}, \"Dosage\": {\"text\": [[\"a higher dose than recommended\"]], \"start\": [[102]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"8 cardiac arrests\", \"6 deaths\"]], \"start\": [[57, 87]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
1477441_2 | CONCLUSIONS: Fixed drug rash induced by methylphenidate is a possible but rare phenomenon. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Fixed drug rash\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methylphenidate\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methylphenidate\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11399735_2 | Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appear\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"pulmonary symptoms\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ticlopidine treatment\"]], \"start\": [[80]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11722307_2 | CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using quetiapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"using\"]], \"start\": [[136]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"quetiapine\"]], \"start\": [[142]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[142]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"agranulocytosis\"]], \"start\": [[114]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"possibility\"]], \"start\": [[99]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
19203515_2 | Acute renal failure is a rare complication following the administration of intravenous immunoglobulin (IVIG). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intravenous immunoglobulin (IVIG)\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"immunoglobulin\"]], \"start\": [[87]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
1751354_3 | We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[130]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"one\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"had an aggravation of the condition\"]], \"start\": [[77]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[135]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[45]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[135]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three\"]], \"start\": [[25]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"psoriasis\"]], \"start\": [[55]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
1661260_1 | Reactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and azathioprine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[41]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Reactivation of cytomegalovirus\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"corticosteroids and azathioprine\"]], \"start\": [[97]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Wegener's granulomatosis\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"azathioprine\"]], \"start\": [[97], [117]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[113]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"azathioprine\"]], \"start\": [[97], [117]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[32]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
8771575_5 | We present a case of respiratory failure occurring in a woman at 16 weeks' gestation who was being treated with nitrofurantoin for a urinary tract infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"respiratory failure\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a woman at 16 weeks' gestation\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"16 weeks' gestation\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"being treated with nitrofurantoin for a urinary tract infection\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[112]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"urinary tract infection\"]], \"start\": [[133]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
10963515_2 | We describe a case of EGE manifested as an allergy to gemfibrozil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"manifested\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a case of EGE\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"EGE\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}}, \"Treatment\": {\"text\": [[\"gemfibrozil\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"gemfibrozil\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"allergy\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
7724306_7 | RESULTS: At our institution, no children appeared with acute INH neurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared with\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"INH\"]], \"start\": [[61]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"INH\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[32]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7249424_3 | Two patients on long-term lithium therapy developed the nephrotic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"long-term lithium therapy\"]], \"start\": [[16]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nephrotic syndrome\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12875956_1 | Acute psychosis associated with levetiracetam. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute psychosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"levetiracetam\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"levetiracetam\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19365885_2 | Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with nonfunctional neuroendocrine tumor\"]], \"start\": [[62]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Hypoglycemia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-acting somatostatin analogues\"]], \"start\": [[24]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"nonfunctional neuroendocrine tumor\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"long-acting somatostatin analogues\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15157248_2 | CASE REPORT: We report a patient who developed a DAT-positive hemolytic episode after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"developed a DAT-positive hemolytic episode\"]], \"start\": [[37]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin\"]], \"start\": [[86]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"oxaliplatin\"], [\"a red cell\"]], \"start\": [[170], [86]], \"entity_id\": [\"T7\", \"T11\"]}, \"Route\": {\"text\": [[\"infusion\"], [\"transfusion\"]], \"start\": [[140], [103]], \"entity_id\": [\"T9\", \"T10\"]}, \"Duration\": {\"text\": [[\"17th cycle\"]], \"start\": [[156]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[129]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"oxaliplatin\"], [\"a red cell\"]], \"start\": [[170], [86]], \"entity_id\": [\"T7\", \"T11\"]}}]}}"
}
]
}
] |
8313300_8 | Regression of thyrotoxic ophthalmopathy following lithium withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Regression\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lithium withdrawal\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"thyrotoxic ophthalmopathy\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
14700673_2 | Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"topiramate\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"topiramate\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"acute-onset myopia and angle closure glaucoma\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17610180_1 | The clinical symptoms of gastric mucosa foveolar hyperplasia due to long-term PGE1 therapy simulate hypertrophic pyloric stenosis. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[61]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"gastric mucosa foveolar hyperplasia\", \"simulate hypertrophic pyloric stenosis\"]], \"start\": [[25, 91]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-term PGE1 therapy\"]], \"start\": [[68]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"PGE1\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7831179_1 | Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"doxorubicin\", \"'low' doses\"]], \"start\": [[25, 76]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"'low' doses\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"cardiomyopathy\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8157823_1 | Generalized argyria after habitual use of AgNO3. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"habitual use of AgNO3\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"AgNO3\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Generalized argyria\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12187348_3 | The authors report the first case of bucillamine-induced giant mammary hyperplasia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"bucillamine\"]], \"start\": [[37]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bucillamine\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"giant mammary hyperplasia\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"first\"]], \"start\": [[23]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
10589077_1 | Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Hydroxyurea (HU) and sodium phenylbutyrate (SPB)\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Hydroxyurea\"], [\"sodium phenylbutyrate\"]], \"start\": [[0], [21]], \"entity_id\": [\"T9\", \"T10\"]}, \"Disorder\": {\"text\": [[\"thalassemia intermedia\"]], \"start\": [[125]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[17]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"Hydroxyurea\"], [\"sodium phenylbutyrate\"]], \"start\": [[0], [21]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"hemoglobin (Hb F) levels\"]], \"start\": [[83]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with thalassemia intermedia\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"fetal\"]], \"start\": [[77]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
1954704_2 | We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"symptoms began\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"myositis\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"within 10 days of receiving leuprolide acetate therapy\"]], \"start\": [[64]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"leuprolide acetate\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"10 days\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"prostate cancer\"]], \"start\": [[123]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
16239768_3 | Venlafaxine-induced urinary incontinence resolved after switching to sertraline. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Venlafaxine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Venlafaxine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"urinary incontinence\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"sertraline\"]], \"start\": [[69]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"Venlafaxine-induced urinary incontinence\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17122225_4 | We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug (phenelzine in one case and duloxetine in the other). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"cyclobenzaprine\", \"duloxetine\"]], \"start\": [[82, 201]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"duloxetine\"]], \"start\": [[201]], \"entity_id\": [\"T18\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[64]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"cyclobenzaprine\"], [\"duloxetine\"]], \"start\": [[82], [201]], \"entity_id\": [\"T15\", \"T18\"]}}]}, \"Subject\": {\"text\": [[\"postoperative patients\"]], \"start\": [[101]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"postoperative\"]], \"start\": [[101]], \"entity_id\": [\"T14\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[23]], \"entity_id\": [\"T19\"], \"value\": \"High\"}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"postoperative patients\"]], \"start\": [[101]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"postoperative\"]], \"start\": [[101]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"cyclobenzaprine\", \"phenelzine\"]], \"start\": [[82, 174]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"cyclobenzaprine\"], [\"phenelzine\"]], \"start\": [[82], [174]], \"entity_id\": [\"T15\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E4\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administration\"]], \"start\": [[64]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"cyclobenzaprine\"], [\"phenelzine\"]], \"start\": [[82], [174]], \"entity_id\": [\"T15\", \"T17\"]}}]}}"
}
]
}
] |
11816261_3 | OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[98]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"metoclopramide was coadministered with sertraline or venlafaxine\"]], \"start\": [[113]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"metoclopramide\"], [\"sertraline\"], [\"venlafaxine\"]], \"start\": [[113], [152], [166]], \"entity_id\": [\"T15\", \"T16\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministered\"]], \"start\": [[132]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"metoclopramide\"], [\"sertraline\"], [\"venlafaxine\"]], \"start\": [[113], [152], [166]], \"entity_id\": [\"T15\", \"T16\", \"T17\"]}}, {\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coadministered\"]], \"start\": [[132]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[113]], \"entity_id\": [\"T15\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome with serious extrapyramidal movement disorders\"]], \"start\": [[32]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"2 cases\"]], \"start\": [[21]], \"entity_id\": [\"T12\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[21]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
11703329_4 | We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[92]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"31-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"unrecognized HMSN-1\"]], \"start\": [[68]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"severe motor neuropathy\"]], \"start\": [[102]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"3 weeks after the first cycle of treatment including 2 mg of vincristine\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"recurrent Hodgkin's lymphoma\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"3 weeks\"]], \"start\": [[126]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"2 mg\"]], \"start\": [[179]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"vincristine\"]], \"start\": [[187]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[102]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
8891729_5 | When the patient was treated again with fludarabine nine months later, the DAT became positive with anti-IgG and anti-C3d antiglobulins after the second course of treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[5]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fludarabine\", \"second course of treatment\"]], \"start\": [[40, 146]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"nine months later\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"the DAT became positive with anti-IgG and anti-C3d antiglobulins\"]], \"start\": [[71]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10566542_2 | This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[93]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"postoperative hypophosphatemia and hypocalcemic tetany\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"alendronate (Fosamax)\", \"after bowel preparation with Fleet Phospho-Soda\"]], \"start\": [[67, 163]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"alendronate\"], [\"Fleet Phospho-Soda\"]], \"start\": [[67], [192]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[187]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"alendronate\"], [\"Fleet Phospho-Soda\"]], \"start\": [[67], [192]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
8496127_1 | Acute dystonic reaction with low-dose pimozide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"low-dose pimozide\"]], \"start\": [[29]], \"entity_id\": [\"T3\"], \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"pimozide\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Acute dystonic reaction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18408649_2 | There are, however, case studies describing patients experiencing recurrences of tics following treatment with atomoxetine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[86]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"recurrences of tics\"]], \"start\": [[66]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"treatment with atomoxetine\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"atomoxetine\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
3680913_2 | Nicotinic acid-induced fulminant hepatic failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Nicotinic acid\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Nicotinic acid\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fulminant hepatic failure\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8969033_2 | Ketanserin in the treatment of protamine-induced pulmonary hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[41]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"protamine\"]], \"start\": [[31]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"protamine\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pulmonary hypertension.\"]], \"start\": [[49]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11122162_3 | We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treat\"]], \"start\": [[47]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"recombinant factor VIIa\"]], \"start\": [[20]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"bleeding\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Time_elapsed\": {\"text\": [[\"immediate and long-term period\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"recombinant factor VIIa\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"PCC-related MI\"]], \"start\": [[110]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"PCC-related MI\"]], \"start\": [[110]], \"entity_id\": [\"T4\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[114]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"PCC\"]], \"start\": [[110]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"PCC\"]], \"start\": [[110]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"MI\"]], \"start\": [[122]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
16882112_1 | Lithium and venlafaxine interaction: a case of serotonin syndrome. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"case\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Lithium and venlafaxine interaction\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Lithium\"], [\"venlafaxine\"]], \"start\": [[0], [12]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"Lithium\"], [\"venlafaxine\"]], \"start\": [[0], [12]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
25407257_3 | The seizures were suspected to be caused by a reduced concentration of VPA in the blood. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"reduced concentration of VPA in the blood\"]], \"start\": [[46]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"reduced concentration\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"VPA\"]], \"start\": [[71]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[18]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
3430507_1 | D-penicillamine induced crescentic glomerulonephritis: report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[16]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"D-penicillamine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"crescentic glomerulonephritis\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19423610_4 | We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"between\"]], \"start\": [[91]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"adverse interaction\"]], \"start\": [[71]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"paroxetine and other agent(s)\"]], \"start\": [[99]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"paroxetine\"], [\"anaesthesia\"]], \"start\": [[99], [155]], \"entity_id\": [\"T10\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"course\"]], \"start\": [[141]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"anaesthesia\"], [\"paroxetine\"]], \"start\": [[155], [99]], \"entity_id\": [\"T9\", \"T10\"]}}]}}"
}
]
}
] |
19331262_3 | Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reaction\"]], \"start\": [[83]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"Neuroleptic malignant syndrome\", \"muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis\"]], \"start\": [[0, 157]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"antipsychotic drugs\"]], \"start\": [[95]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"antipsychotic\"]], \"start\": [[95]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[50]], \"entity_id\": [\"T13\"], \"value\": true}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[62]], \"entity_id\": [\"T17\"], \"value\": \"High\"}}"
}
]
}
] |
11545487_2 | Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Indinavir\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Indinavir\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nephrolithiasis and chronic interstitial nephritis\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19904536_2 | Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"unpredictable side effects\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[41]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
8678015_1 | Albendazole-induced pseudomembranous colitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Albendazole\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Albendazole\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pseudomembranous colitis\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17364199_1 | Tuberculous uveitis after treatment with etanercept. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Tuberculous uveitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"etanercept\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"etanercept\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3301251_3 | Salicylate-induced hepatotoxicity is reviewed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Salicylate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Salicylate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19531695_2 | To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"flecainide\", \"interaction with paroxetine\"]], \"start\": [[22, 89]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"flecainide\"], [\"paroxetine\"]], \"start\": [[22], [106]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[89]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"paroxetine\"], [\"flecainide\"]], \"start\": [[106], [22]], \"entity_id\": [\"T12\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"delirium\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
8098286_3 | We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta-blocker, celiprolol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"hypersensitivity pneumonitis\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"celiprolol\"]], \"start\": [[106]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"celiprolol\"]], \"start\": [[106]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19224802_3 | dexmedetomidine is used to provide sedation for pediatric patients undergoing nonpainful radiological imaging studies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used to\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"provide sedation\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dexmedetomidine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"dexmedetomidine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"pediatric patients undergoing nonpainful radiological imaging studies\"]], \"start\": [[48]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
16882112_5 | A 71-year-old woman developed serotonin syndrome while receiving treatment with moderate doses of lithium and venlafaxine for refractory depression. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A 71-year-old woman\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"71-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"moderate doses of lithium and venlafaxine\"]], \"start\": [[80]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"refractory depression\"]], \"start\": [[126]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"moderate doses\"]], \"start\": [[80]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[98], [110]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[106]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[98], [110]], \"entity_id\": [\"T18\", \"T19\"]}}]}}"
}
]
}
] |
8013261_2 | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Four years after the beginning of IFN therapy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"Four years after\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"IFN\"]], \"start\": [[34]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[47]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[47]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15644988_1 | Tardive dyskinesia in 2 patients treated with ziprasidone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Tardive dyskinesia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ziprasidone\"]], \"start\": [[46]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ziprasidone\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"2 patients\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15866658_3 | The mean time from starting MMF to the development of neutropenia was 4 months. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[39]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"MMF\"]], \"start\": [[28]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"MMF\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"neutropenia\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9037299_1 | Fulminant hepatic failure associated with bicalutamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Fulminant hepatic failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bicalutamide\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bicalutamide\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17366681_1 | A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"melanonychia and onycholysis\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pemetrexed for lung cancer\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"lung cancer\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"pemetrexed\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |